Publications by authors named "Ralph Zinner"

Claim this Profile
P
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.
Vivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, Michael A Kiebish, Leonardo O Rodrigues, Ralph Zinner

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.
Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, Kathryn Nunes, Pablo Llerena

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds.
Ibrahim A Imam, Shatha Al Adawi, Xiaoqi Liu, Sally Ellingson, Christine F Brainson, Ralph Zinner

Proteins· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing Survey-Based Mobile Interfaces for Rural Patients With Cancer Using Apple's ResearchKit and CareKit: Usability Study.
Alyssa Donawa, Christian Powell, Rong Wang, Ming-Yuan Chih, Reema Patel, Ralph Zinner

JMIR Form Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing

NPJ Precis Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Adam J Luginbuhl, Jennifer M Johnson, Larry A Harshyne, Alban J Linnenbach, Sanket K Shukla, Ralph Zinner

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
Christine F Brainson, Bin Huang, Quan Chen, Laurie E McLouth, Chunyan He, Ralph G Zinner

Clin Lung Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment.
Ronald E Myers, Shailesh M Advani, Pamela Myers, Preethi Selvan, Gregory Garber, Ralph Zinner

J Pers Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of the MET/ Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, Wendy Xiong, Li Xu, Ralph Zinner

Onco Targets Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Filip Janku, Divya Sakamuri, Shumei Kato, Helen J Huang, S Greg Call, Ralph G Zinner

Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Hua Shen, Gao-Chan Wang, Xiang Li, Xin Ge, Meng Wang, Ralph G Zinner

Oncogene· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect.
Dante J Merlino, Jennifer M Johnson, Madalina Tuluc, Stacey Gargano, Robert Stapp, Ralph Zinner

Front Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy.
Grace Lu-Yao, Ginah Nightingale, Nikita Nikita, Scott Keith, Krupa Gandhi, Ralph Zinner

J Geriatr Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction.
Lei Huang, David Brunell, Clifford Stephan, James Mancuso, Xiaohui Yu, Ralph Zinner

Bioinformatics· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, Barry D Nelkin, Vivek Subbiah, Ralph Zinner

Clin Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, Aung Naing, Vivek Subbiah, Ralph G Zinner

Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.
Goldy C George, Adrianna Buford, Kenneth Hess, Sarina A Piha-Paul, Ralph Zinner

JCO Clin Cancer Inform· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.
Jyoti D Patel, Luis Paz-Ares, Ralph G Zinner, Fabrice Barlesi, Andrew G Koustenis

Clin Lung Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
Shumei Kato, Denis L Jardim, Faye M Johnson, Vivek Subbiah, Sarina Piha-Paul, Ralph Zinner

Invest New Drugs· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Rachna T Shroff, Mark Yarchoan, Ashley O'Connor, Denise Gallagher, Marianna L Zahurak, Ralph Zinner

Br J Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer in the Older Patient.
Julie A Barta, Ralph G Zinner, Michael Unger

Clin Geriatr Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Vikas Dembla, Roman Groisberg, Ken Hess, Siqing Fu, Jennifer Wheler, Ralph Zinner

Sci Rep· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.
Jennifer B Goldstein, Chad Tang, Kenneth R Hess, David Hong, Vivek Subbiah, Ralph Zinner

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
Vivek Subbiah, Christian Meyer, Ralph Zinner, Funda Meric-Bernstam, Marianna L Zahurak

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Rachna T Shroff, Mark Yarchoan, Ashley O'Connor, Denise Gallagher, Marianna L Zahurak, Ralph Zinner

Br J Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis